JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB310897

PE Anti-Monoamine Oxidase A / MAO-A antibody [EPR7101]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Monoamine Oxidase A/MAO-A antibody - conjugated to PE.

View Alternative Names

Amine oxidase [flavin-containing] A, Monoamine oxidase type A, MAO-A, MAOA

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Monoamine Oxidase A/MAO-A antibody [EPR7101]

  • HRP

    HRP Anti-Monoamine Oxidase A/MAO-A antibody [EPR7101]

  • 660 APC

    APC Anti-Monoamine Oxidase A / MAO-A antibody [EPR7101]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Monoamine Oxidase A / MAO-A antibody [EPR7101]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Monoamine Oxidase A / MAO-A antibody [EPR7101]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Monoamine Oxidase A / MAO-A antibody [EPR7101]

  • Unconjugated

    Anti-Monoamine Oxidase A/MAO-A antibody [EPR7101]

  • Carrier free

    Anti-Monoamine Oxidase A/MAO-A antibody [EPR7101] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR7101

Isotype

IgG

Conjugation

PE

Excitation/Emission

Ex: 480;565nm, Em: 578nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Product details

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Monoamine Oxidase A (MAO-A) also known as MAO protein is an enzyme that degrades neurotransmitters through oxidative deamination. It possesses a mass of approximately 59 kDa. This enzyme is found localized in the outer mitochondrial membrane of cells specifically in high concentrations in the brain liver and intestine. MAO-A plays an important role in the breakdown of monoamine neurotransmitters such as serotonin norepinephrine and dopamine which are critical for normal brain function.
Biological function summary

MAO-A acts to maintain proper neurotransmitter levels by catalyzing the oxidative deamination of monoamines. It is not part of a larger protein complex but functions independently to influence monoamine balance. Through its enzymatic activity MAO-A regulates several physiological processes including mood and emotional responses by controlling neurotransmitter availability and preventing their accumulation to neurotoxic levels.

Pathways

MAO-A operates within the catabolic pathways that reduce the bioavailability of monoamines. It pairs with proteins like Catechol-O-methyltransferase (COMT) in the metabolic degradation of catecholamines. This pathway is integral to managing the equilibrium of mood-related neurotransmitters and involves complex interactions with other enzymatic systems including MAO-B which targets different substrates.

MAO-A is closely associated with psychiatric conditions such as depression and anxiety. Altered MAO-A activity can dysregulate monoamine levels contributing to these disorders. Additionally research links MAO-A dysregulation to neurodegenerative diseases like Parkinson's disease where imbalances in monoamine levels play a role. This enzyme interacts with proteins involved in early stages of these diseases highlighting its potential as a target for therapeutic interventions using MAO inhibitors.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed : 18391214, PubMed : 20493079, PubMed : 24169519, PubMed : 8316221). Preferentially oxidizes serotonin (PubMed : 20493079, PubMed : 24169519). Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity).
See full target information MAOA

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com